Ontario has become the first province in Canada to publicly cover Olumiant (baricitinib), the first medicine approved for adults with severe alopecia areata, marking a milestone that may influence other provinces to follow suit.
Eli Lilly Canada Inc. confirmed that Ontario’s inclusion of Olumiant on its public drug formulary makes it the only publicly reimbursed treatment for severe alopecia areata in the country. Health Canada authorized Olumiant for adult patients with the condition on January 26, 2024.
The approval was supported by Lilly’s BRAVE-AA1 and BRAVE-AA2 Phase 3 trials, which studied 1,200 adults with severe disease, defined as at least 50 percent scalp hair loss according to the Severity of Alopecia Tool (SALT) score.
On October 2, 2024, Canada’s Drug Agency (CDA-AMC) issued a positive reimbursement recommendation for Olumiant as a first-line advanced therapy. Following negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA), a letter of intent was signed on November 10, 2025, marking the first time a medicine for severe alopecia areata completed public reimbursement negotiations in Canada.
Ontario’s decision is being hailed by advocates and clinicians alike. “Ontario is taking the lead in giving people with alopecia areata access to an effective treatment option, Olumiant,” said Lilly Canada spokesperson Merlet. She emphasized that the company encourages other public drug plans to act swiftly so patients can access the therapy.
Clinicians describe alopecia areata as an immune-mediated condition that can significantly affect quality of life. “We have seen clinical benefit from targeted systemic therapies such as JAK inhibitors — including Olumiant — in cases of severe alopecia areata,” said Dr. Beecker. She noted that Ontario’s public listing represents an important step toward broader access to these therapies.
Patient advocates also emphasize the psychosocial impact of the condition. “Alopecia areata is more than just hair loss,” said Harrison, noting that hair is closely tied to personal identity. She added that patients across Canada are eager for nationwide access to Olumiant.
Despite federal approvals and national reimbursement frameworks, access remains inconsistent. In Québec, medications prescribed for alopecia are explicitly excluded from the public drug formulary (RAMQ) under section 6.2.4.1. As a result, Olumiant is not currently evaluated for public reimbursement by the Institut national d’excellence en santé et services sociaux (INESSS), although federal public access programs can provide coverage. Lilly is working with Québec health authorities to reconsider this exclusion, citing inequitable access for residents living with severe alopecia areata.
Ontario’s decision sets a precedent for public funding of targeted therapies for severe alopecia areata, potentially shaping the treatment landscape across Canada.
